Find out why OCREVUS may be the right choice for treating your primary progressive multiple sclerosis (PPMS). See results and understand how OCREVUS was evaluated in a clinical trial.
†OCREVUS was studied against a placebo. A placebo is a substance or treatment that has no active medicine. It is common for treatment to be compared with a placebo when there are no existing approved treatments to compare it with. Disability progression was measured using a tool called the Expanded Disability Status Scale (EDSS). Disability progression was confirmed 3 months after the initial neurological worsening.
‡Disability progression was also confirmed after 6 months.
Why is this important?
Disability progression was delayed for people taking OCREVUS as compared with those taking placebo.
Disability progression is the increase in physical disability that
happens over time for people with MS. How and when it happens is
different for everyone.
How is disability progression measured in clinical studies?
Disability progression is measured using a tool called the Expanded
Disability Status Scale (EDSS). It assesses your functionality or
changes to function in the areas listed below. OCREVUS was not proven
to individually reduce each of these measured endpoints.
- Muscle weakness or difficulty moving limbs
- Tremor or loss of coordination
- Problems with speech, swallowing, or involuntary eye movements
- Numbness or loss of sensations
- Bowel and bladder function
- Visual function - problems with sight
- Cerebral functions - problems with thinking and memory
OCREVUS increases your risk of getting upper respiratory tract infections, lower respiratory tract infections, skin infections, and herpes infections. Tell your healthcare provider if you have an infection or have any of the following signs of infection including fever, chills, a cough that does not go away, or signs of herpes (such as cold sores, shingles, or genital sores). These signs can happen during treatment or after you have received your last dose of OCREVUS. If you have an active infection, your healthcare provider should delay your treatment with OCREVUS until your infection is gone. Visit Safety & Side Effects for more information.
OCREVUS reduced the volume of T2 hyperintense lesions, while T2 lesion volume increased in people taking placebo.
The average change in volume of T2 lesions was -0.39 cm3 for OCREVUS compared with 0.79 cm3 for placebo.‡
‡OCREVUS was evaluated in a study including 732 people who were treated with OCREVUS or placebo for at least 120 weeks.
Lesions in MS
- Lesion volume is the total amount of lesion area, including both old and new lesions, and is measured using magnetic resonance
- T2 hyperintense lesions may reflect new inflammation or older, chronic lesions which are a sign of scarring from previous MS activity
Here are the people included in the study:
- 732 people (488 taking OCREVUS, 244 taking placebo)
- 18-55 years of age
- Average time since people experienced the start of symptoms was about 7 years
- Had not previously received MS disease-modifying treatment (88%) and those who had (12%)
Why this is important:
- Studied in a large group of people
- Studied in a variety of people who have MS
- Study included people who had not been taking a treatment and those who had